<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50-biomedicines-08-00060">
 <label>50.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Crommentuijn</surname>
    <given-names>M.H.</given-names>
   </name>
   <name>
    <surname>Kantar</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Noske</surname>
    <given-names>D.P.</given-names>
   </name>
   <name>
    <surname>Vandertop</surname>
    <given-names>W.P.</given-names>
   </name>
   <name>
    <surname>Badr</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>WÃ¼rdinger</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Maguire</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Tannous</surname>
    <given-names>B.A.</given-names>
   </name>
  </person-group>
  <article-title>Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model</article-title>
  <source>Mol. Ther. Oncol.</source>
  <year>2016</year>
  <volume>3</volume>
  <fpage>16017</fpage>
  <pub-id pub-id-type="doi">10.1038/mto.2016.17</pub-id>
 </element-citation>
</ref>
